EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Time‐Restricted Eating to Improve Metabolic Abnormalities in Polycystic Ovarian Syndrome (TimeMAP)

Ruairí Floyd iD, Adam Dyer iD, James Gibney iD, Fatimah Alawami, Lisa Owens iD, Niamh Phelan iD, Ana Rakovac iD, Patrick Swan iD, Carel W LeRoux iD, Lucy Ann Behan iD, Sinead N Duggan iD

Clinical Endocrinology · 2026

DOI: 10.1111/cen.70094 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Ruairí Floyd und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Robert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Meath Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Time‐restricted eating (TRE) represents a novel intervention that may improve hyperinsulinaemia and reduce weight, but has not been studied in polycystic ovarian syndrome (PCOS). In a randomised interventional study (NCT05126199 [1]), we investigated the feasibility of TRE in PCOS including recruitment, compliance, safety, drop‐out rate, and effect on insulin‐related parameters, anthropometrics, nutritional intake and metabolic indices.

Methods

Participants were randomised to a 12‐week TRE regimen (18 h fast/6 h eating window) or ‘ad libitum’ regimen (no time‐restriction), and then crossed over to the alternative regimen for a further 12 weeks.

Results

TRE was a feasible intervention with near‐total compliance in those completing the intervention; however, there were considerable difficulties with recruitment. A total of 70 were eligible to participate, of which ultimately 15 were recruited, and 11 completed the study (4 [27%] drop‐outs due to commitment/study duration). There were no serious adverse events in the TRE group. Compliance [%(SD)] with TRE was 94.7(4.5)%, and 10 participants were keen to continue the intervention post‐study. Whilst the study was not powered to detect changes in metabolic or anthropometric indices, exploratory analysis showed a decrease in HbA1c ( p = 0.04), weight ( p = 0.001), BMI ( p = 0.001), hip circumference ( p = 0.05) and waist circumference ( p = 0.001) in the TRE group compared to the ad libitum eating group.

Conclusion

In a 12‐week cross‐over feasibility study, TRE was a safe and feasible intervention. Recruitment was challenging and with limited numbers, the TRE group showed a decrease in HbA1c and anthropometric indices compared to the ‘ad libitum’ group. Trial Registration: NCT05126199.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeHumansFemaleIntermittent FastingAdultYoung AdultCross-Over StudiesBlood GlucoseInsulinInsulin ResistancePatient Compliance

Stichwörter der Autor:innen

PCOSinsulin sensitivityintermittent fastingtime‐restricted eating

Substanzen

Blood GlucoseInsulin

Autor:innen und Institutionen

  • Department of Endocrinology, Robert Graves Institute of Endocrinology, Tallaght University Hospital, Dublin, Ireland.
  • Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.
  • Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.
  • Department of Endocrinology, St. James's Hospital, Dublin, Ireland.
  • Department of Clinical Chemistry, Tallaght University Hospital, Dublin, Ireland.
  • Diabetes Complications Research Centre University College Dublin, Dublin, Ireland.

ORCID-Profile: Ruairí Floyd, Adam Dyer, James Gibney, Lisa Owens, Niamh Phelan, Ana Rakovac, Patrick Swan, Carel W LeRoux, Lucy Ann Behan, Sinead N Duggan

Förderung

  • The Meath Foundation

Zitieren

APA

Floyd, R., Dyer, A., Gibney, J., Alawami, F., Owens, L., Phelan, N., Rakovac, A., Swan, P., LeRoux, C. W., Behan, L. A., & Duggan, S. N. (2026). Time‐Restricted Eating to Improve Metabolic Abnormalities in Polycystic Ovarian Syndrome (TimeMAP). Clinical Endocrinology. https://doi.org/10.1111/cen.70094

Vancouver

Floyd R, Dyer A, Gibney J, Alawami F, Owens L, Phelan N, et al. Time‐Restricted Eating to Improve Metabolic Abnormalities in Polycystic Ovarian Syndrome (TimeMAP). Clinical Endocrinology. 2026. doi:10.1111/cen.70094

BibTeX
@article{Floyd2026,
  author = {Floyd, Ruairí and Dyer, Adam and Gibney, James and Alawami, Fatimah and Owens, Lisa and Phelan, Niamh and Rakovac, Ana and Swan, Patrick and LeRoux, Carel W and Behan, Lucy Ann and Duggan, Sinead N},
  title = {Time‐Restricted Eating to Improve Metabolic Abnormalities in Polycystic Ovarian Syndrome (TimeMAP)},
  journal = {Clinical Endocrinology},
  year = {2026},
  doi = {10.1111/cen.70094}
}
Kostenlos starten →